Novo Nordisk sees 'painful' US price cuts for Wegovy as investment in the future

Core Viewpoint - Novo Nordisk's CEO Mike Doustdar indicated that the price reductions for the obesity drug Wegovy in the U.S. are negatively impacting the company's financial results, but he believes this strategy will lead to greater access to the medication in the future [1] Group 1 - The price reductions for Wegovy are described as "painful" for the company's financial performance [1] - The CEO expresses hope that these reductions will serve as an investment in the future by increasing access to the drug for more individuals [1]